| Diabetes Mellitus
Levemir vs Semglee
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Levemir vs Semglee with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSemglee has a higher rate of injection site reactions vs Levemir based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Semglee but not Levemir, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Levemir
Semglee
At A Glance
SC injection
Once or twice daily
Long-acting basal insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus (Type 1) Approximately one-third to one-half of the total daily insulin dose SC once or twice daily in combination with rapid-acting or short-acting insulin; initial total daily dose 0.2-0.4 units/kg in insulin-naive patients.
Diabetes Mellitus (Type 2) 10 units (or 0.1-0.2 units/kg) SC once daily in the evening or divided into a twice-daily regimen in patients inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist.
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use concomitantly with short-acting premeal insulin.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily at the same time each day for insulin-naive patients; individualize based on metabolic needs and glycemic goals.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin detemir or any excipient in LEVEMIR, including reactions such as anaphylaxis
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in Semglee
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, headache, pharyngitis, influenza-like illness, abdominal pain, hypoglycemia
Serious Severe hypoglycemia, anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, shock, lipodystrophy, peripheral edema, hypokalemia
Postmarketing Medication errors with accidental administration of other insulins instead of LEVEMIR, localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection into amyloidosis sites
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache
Serious Severe hypoglycemia, anaphylaxis and generalized hypersensitivity reactions, hypokalemia, peripheral edema, lipodystrophy
Postmarketing Medication errors with rapid-acting insulins administered instead of insulin glargine, localized cutaneous amyloidosis at injection site
Pharmacology
Long-acting basal human insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; prolonged duration of action is mediated by self-association of drug molecules at the injection site and albumin binding in the bloodstream.
Insulin glargine-yfgn is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Levemir
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (1/12) · Qty limit (0/12)
Semglee
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (3/12) · Qty limit (6/12)
UnitedHealthcare
Levemir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Semglee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Levemir
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (1/3) · Qty limit (0/3)
Semglee
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Levemir.
No savings programs available for Semglee.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LevemirView full Levemir profile
SemgleeView full Semglee profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.